Cart
sales@molnova.com
ML399
CAS No. 1560968-49-1
ML399( VU0516340 )
Catalog No. M12219 CAS No. 1560968-49-1
ML399 (VU0516340) is a potent and cell penetrant menin-MLL inhibitor with IC50 of 90 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1444 | Get Quote |
|
| 50MG | 1841 | Get Quote |
|
| 100MG | 2325 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameML399
-
NoteResearch use only, not for human use.
-
Brief DescriptionML399 (VU0516340) is a potent and cell penetrant menin-MLL inhibitor with IC50 of 90 nM.
-
DescriptionML399 (VU0516340) is a potent and cell penetrant menin-MLL inhibitor with IC50 of 90 nM; shows improved potency and DMPK properties; a chemical probe for in vivo proof-of-mechanism studies.
-
In Vitro——
-
In Vivo——
-
SynonymsVU0516340
-
PathwayChromatin/Epigenetic
-
TargetHMTase
-
RecptorHMTase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1560968-49-1
-
Formula Weight445.538
-
Molecular FormulaC27H28FN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC1=CC=C(OCCCN2CCC([C@@](O)(C3=CC=CC(F)=C3)C4=NC=CC=C4)CC2)C=C1
-
Chemical Name(R)-4-(3-(4-((3-Fluorophenyl)(hydroxy)(pyridin-2-yl)methyl)piperidin-1-yl)propoxy)benzonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Senter T, et al. Probe Reports from the NIH Molecular Libraries Program [Internet].
2. Senter T, et al. Bioorg Med Chem Lett. 2015 Jul 1;25(13):2720-5.
molnova catalog
related products
-
NV03
NV03 is a small-molecule antagonist of the H3K9me3 binding to UHRF1 tandem tudor domain with Kd of 2.4 uM.
-
LEM-14
LEM-14 is a specific inhibitor of histone lysine methyltransferase NSD2 (MMSET/WHSC1) with in vitro IC50 of 132 uM.
-
CMP-5
CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival.
